EFFECTS OF LOSARTAN ON DIABETIC NEUROPATHY

By

Fahima Sultana

ID: 19346035

A thesis submitted to the ‘School of Pharmacy’ in partial fulfilment of the requirements of the degree of Bachelor's in Pharmacy.

School of Pharmacy

BRAC University

July 2025

Declaration

It is hereby declared that

1. The thesis submitted is my/our own original work while completing the degree at BRAC University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I/We have acknowledged all main sources of help.

Student's Full Name & Signature:

Student Full Name: Fahima Sultana
Student ID: 19346035

Approval

The thesis/project titled "EFFECTS OF LOSARTAN ON DIABETIC NEUROPATHY" submitted by Fahima Sultana (ID: 19346035) of Spring 2025 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of School of Pharmacy.

Examining Committee:

Supervisor:
(Member)

_____
Full Name: Sabrina Sharmin, PhD
Associate Professor, School of Pharmacy
BRAC University

Program Coordinator:
(Member)

_____
Full Name: Namara Mariam Chowdhury
Senior Lecturer, School of Pharmacy
BRAC University

Departmental Head:
(Chair)

_____
Full Name: A F M Yusuf Haider, PhD
Acting Dean, School of Pharmacy
BRAC University

Ethics Statement

This thesis examines current published research on the 'Effects of Losartan on diabetic neuropathy'. No original experiments were performed that involved human or animal subjects. Every source utilized in this review was acquired from credible, peer-reviewed journals, publications, and established databases. Correct recognition and citation have been given in line with the academic integrity principles established by BRAC University and referencing standards like the Publication Manual of the American Psychological Association (APA).

Abstract

Diabetic neuropathy is a prevalent and disabling complication of diabetes mellitus, greatly impacting patients' quality of life and raising the risk of morbidity. Losartan, a blocker of angiotensin II receptors (ARB), is commonly prescribed for treating hypertension and diabetic nephropathy, but new studies indicate it might also have a positive impact on diabetic neuropathy management. This analysis thoroughly assesses and integrates existing scientific studies on the impact of Losartan on diabetic neuropathy, highlighting its possible mechanisms, effectiveness, and safety profile. Current research suggests that Losartan might alleviate neuropathic symptoms by influencing blood pressure regulation, enhancing microvascular circulation, and blocking oxidative stress and inflammatory processes. Nonetheless, results from clinical and preclinical studies are not completely uniform, and additional high-quality randomized controlled trials are necessary to elucidate Losartan’s function in treating and preventing diabetic neuropathy. This review emphasizes existing evidence deficiencies and proposes avenues for future investigation.

Keywords: Diabetic Neuropathy, Losartan, Angiotensin II Receptor Blocker, Hypertension, Microvascular Complications, Neuropathic Pain, Review

Dedication

This thesis is dedicated to almighty Allah, my family, friends and teachers, whose support and guidance have made this work possible.

Acknowledgement

I want to sincerely thank almighty Allah first and then express my appreciation to my supervisor, Dr. Sabrina Sharmin, for her valuable guidance, support, and helpful feedback during this project.

I also appreciate the faculty and staff of 'School of Pharmacy, BRAC University' for offering essential resources and a nurturing academic atmosphere.

I extend my sincere gratitude to my family and friends for their constant support, compassion, and encouragement throughout my study period.

I appreciate all the authors and researchers whose contributions have enhanced this review.

Table of Contents

4.2 MOA : Target Site, Biological Effect, Pharmacodynamics, Selectivity)

- **Chapter 5: Advance Technology**

  5.1 Combination Therapies, CRISPR & Gene Therapy, Personalized Dosage, Nanotechnology based drug delivery

- **Chapter 6: Limitations & Future Indications**

  6.1 Limitations: Cost & Availability, Age Restrictions, Genetic Factors, Tolerance Development

  6.2 Future Indications: Ongoing & Future Research (Trials, Repurposing studies), Regulatory & Approval Status, Competitor Drugs

- **Chapter 7: Conclusion**
- **References**

List of Tables

List of Figures

Chapter 1: Introduction

Diabetic neuropathy is a frequent long-term complication of diabetes, marked by harm to the peripheral nerves. It typically manifests as distal symmetric polyneuropathy impacting the legs and feet, resulting in sensory deficits, pain, and occasionally motor dysfunction. Nature Reviews Primers actually define diabetic neuropathy as "a reduction of sensory function starting in the lower extremities" and mention that it affects at least 50% of patients with prolonged diabetes. Consequently, neuropathy is regarded as one of the most common complications associated with diabetes. The widespread occurrence of asymptomatic nerve damage indicates that a significant number of diabetes patients face the risk of ulcers, amputations, and other complications if neuropathy is not identified and treated.

Diabetes is the primary cause of peripheral neuropathy worldwide. The length of diabetes, management of blood sugar levels, and existing cardiovascular risk factors are independently linked to the onset and advancement of diabetic peripheral neuropathy and cardiovascular autonomic neuropathy. Diabetic neuropathies refer to a group of nerve conditions resulting from diabetes. Numerous studies have demonstrated that strict glucose management in patients with type 2 diabetes mellitus decreases the advancement of microvascular complications. In the peripheral nervous system, sensory neurons, Schwann cells, and microvascular endothelium are susceptible to oxidative and inflammatory stress when altered metabolic substrates are present. Effective glycemic management can reduce the occurrence of diabetic neuropathy; however, over half of all individuals with diabetes still experience this complication. Epidemiological studies indicate that the length and intensity of hyperglycemia are significant risk factors for the onset of diabetic neuropathy. Recent studies have broadened the identified risk factors beyond hyperglycemia to encompass dyslipidemia, hypertension, and smoking. Additional risk factors such as an increased body-mass index,

elevated von Willebrand factor levels, and a higher urinary albumin excretion rate are all significantly linked to the cumulative incidence of neuropathy. The EURODIAB Prospective Complications Study Baseline data, along with other studies, indicates a significant link between neuropathy and various microvascular complications, implying a shared pathogenic mechanism. Angiotensin receptor blockers (ARB) counteract microalbuminuria and avert nephropathy. Continuing with the same analogy, ACE inhibitors ought to be advantageous in all vascular areas, encompassing neuropathy and retinopathy; and evidence has been reported in their favor. The antihypertensive effectiveness of losartan, an angiotensin II antagonist (AT-antagonist), is comparable to that of ACE inhibitors; however, its effectiveness in neuropathy has not been thoroughly researched. Recently, several researchers discovered that the AT2R antagonist may be especially effective in treating chronic pain and hypersensitivity linked to abnormal nerve growth.

Losartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with an established history in diabetes care. It was the first ARB approved by the FDA (in 1995) for hypertension. Over the past decades, losartan has been widely used to control blood pressure and protect the kidneys in diabetic patients. For example, Ripley and Hirsch (2010) report that losartan reduces proteinuria and slows the progression of diabetic nephropathy. Indeed, losartan (and other ARBs) is officially indicated for managing chronic kidney disease in hypertensive patients with type 2 diabetes. Beyond nephropathy, RAS blockade with losartan has also been shown to slow diabetic retinopathy progression, demonstrating its ability to improve microvascular outcomes in diabetes. In summary, losartan’s historical role in diabetic complications has focused on vascular protection – particularly renal protection – which provides context for considering its effects on other diabetes-related complications.

Diabetic nephropathy (DN) is a significant factor of illness and death impacting 30-50% of type 1 and 25% of type 2 diabetes patients. The advancement of DN can be avoided or postponed through proper metabolic management, limiting dietary protein, and using effective antihypertensive therapy. Angiotensin converting enzyme inhibitors (ACEIs) are also successful in preventing DN regardless of their blood pressure-lowering effects. ACEI reduces microalbuminuria levels and hinders the advancement to proteinuria during the microalbuminuric stage of diabetic nephropathy (DN). Losartan is an antagonist of the angiotensin type 1 receptor (AT 1). It exhibits a dose-dependent effect on lowering blood pressure, evidenced by both experimental and clinical research. The kidney protective benefits of ACEIs are well recognized, yet the mechanisms behind this effect remain a topic of discussion. It is widely recognized that the systemic renin/angiotensin pathway is inactive in individuals with diabetes. Activation of local renin/angiotensin systems or heightened sensitivity to angiotensin II are among the mechanisms suggested to clarify the connection between the renin/angiotensin system, ACE inhibitors, and diabetic nephropathy. ACEIs lower the heightened intraglomerular capillary pressure through their vasodilatory action on efferent renal arterioles; this outcome directly stems from the inhibition of the renin/angiotensin system. Nonetheless, this haemodynamic mechanism fails to account for all the impacts of ACEI on the diabetic kidney, including the prevention of glomerular hypertrophy or the restoration of impaired charge selectivity. Inhibition of the kininase II enzyme by ACE inhibitors may result in elevated local bradykinin and nitric oxide levels, potentially beneficial in diabetic nephropathy. Nonetheless, the specific antagonist of AT 1 losartan lacks those biochemical effects. Nonetheless, in experimental research, losartan demonstrated an effect similar to that of ACE inhibitors.

Despite advances in glucose lowering, treatment options directly targeting diabetic neuropathy remain limited. Tight glycemic control can prevent or delay neuropathy in type 1 diabetes, but it has only modest benefits in type 2 diabetes. Symptomatic pain management is available, but there is no proven therapy to reverse nerve damage. This treatment gap motivates investigation of agents like losartan that may act on neuropathy mechanisms. The renin-angiotensin system influences vascular tone, inflammation, oxidative stress, and advanced glycation end-products – all of which are implicated in neuropathy. Angiotensin receptor blockers have vasodilatory and antioxidant actions, suggesting they could confer neuroprotective effects. Indeed, experimental studies indicate that losartan can improve nerve blood flow, increase nerve capillary density, and support nerve regeneration in diabetic models. These findings provide a plausible mechanism for benefit. Early clinical studies have been mixed: some short-term trials of losartan showed little improvement in neuropathy measures. Nonetheless, recent reviews conclude that "ARBs might be a helpful tool for preventing and delaying the progression of diabetic neuropathy". Given this rationale and the unmet need for neuropathy treatments, further research on losartan's effects in diabetic neuropathy is warranted.

The development of diabetic nephropathy involves multiple factors, with the renin−angiotensin−aldosterone system being significant. Chronic proteinuria is the defining feature of diabetic nephropathy, a disorder noted for an increasing blood pressure, a decreasing glomerular filtration rate, and a heightened likelihood of serious or non-serious cardiovascular incidents. The level of proteinuria is strongly related to the occurrence of renal and cardiovascular events. Moreover, a decrease in proteinuria is linked to a slower decline in the glomerular filtration rate and a delay in the progression to end-stage renal disease. Moreover, reducing proteinuria is linked to better cardiovascular results in individuals with

diabetic nephropathy and high blood pressure. Consequently, a decrease in proteinuria has been commonly utilized as a substitute end point for kidney protection. In the last twenty years, the prognosis for diabetes patients with microalbuminuria or macroalbuminuria has enhanced, likely due to prompt and vigorous management of blood pressure and inhibition of the renin−angiotensin−aldosterone system. Nonetheless, a significant unmet need remains to create strategies aimed at preventing diabetic nephropathy and its advancement to end-stage renal disease. Diabetic nephropathy continues to be the primary cause of end-stage renal disease in developed countries. The purpose of this trial was to assess the possible kidney-protective effects of direct renin inhibition using aliskiren in individuals with hypertension, type 2 diabetes, and proteinuria who were already on the highest advised renoprotective therapy with losartan (100 mg daily) along with optimal hypertension management. Furthermore, the safety of dual blockade of the renin−angiotensin−aldosterone system was observed and documented.

The aim of the present study is to investigate the effects of losartan on diabetic neuropathy. In line with prior work (e.g., Cavusoglu et al., 2015) that explicitly set out “to evaluate the effect of the angiotensin receptor blocker losartan on diabetic neuropathy”, this research will assess whether losartan treatment can ameliorate neuropathic deficits in diabetes. The specific objectives of the study are to- 1. Measure changes in peripheral nerve function. Assess the impact of losartan on electrophysiological measures (e.g., nerve conduction velocity) or histological markers of nerve integrity. 2. Evaluate neuropathic symptoms. Determine whether losartan alters clinical symptoms of neuropathy, such as pain severity or sensory thresholds. 3. Analyze biochemical indicators. Examine biomarkers of nerve damage, oxidative stress, or inflammation to see if losartan effects underlying pathophysiology. 4. Compare with controls. Contrast outcomes in losartan-treated diabetic

subjects versus controls or placebo to establish any specific benefit of ARB therapy beyond standard care. Together, these aims and objectives will clarify whether losartan holds therapeutic potential for diabetic neuropathy, expanding on its established role in other diabetic complications.

Chapter 2: Methodology

This study was carried out via a systematic review of available literature, encompassing peer-reviewed journals, clinical trials, and pharmacological databases like PubMed, ScienceDirect, and Cochrane Library. The research encompassed randomized controlled trials (RCTs), meta-analyses, cohort studies, and reviews conducted from 2000 to 2024. Terms utilized included "Losartan", "diabetic neuropathy", "angiotensin receptor blockers (ARBs)", and "neuropathic pain". Studies were included if they examined the pathophysiology of diabetic neuropathy, the pharmacological effects of Losartan, and clinical results in diabetic groups.

Chapter 3: Disease

a) Diagnosis

Identifying and Assessment: Diabetic neuropathy (DN) is a long-lasting, advancing complication of diabetes mellitus that mainly impacts peripheral nerves as a result of extended damage caused by hyperglycemia. It is among the most frequent complications in chronic diabetes, particularly in those with inadequate glycemic management. Identifying DN necessitates a thorough strategy that integrates patient-reported symptoms, clinical evaluations, and objective diagnostic methods. Patients frequently describe sensations like burning, stabbing, or tingling in their hands and feet, which can intensify during the night. In more severe instances, there might be a total absence of protective feeling, raising the likelihood of ulcers and infections.

Healthcare providers start with a comprehensive medical history and symptom assessment, then conduct a physical exam that emphasizes neurological function. Typical instruments for bedside assessment feature the 10g Semmes-Weinstein monofilament test for measuring pressure sensitivity, the 128 Hz tuning fork for testing vibratory perception, and the application of pinprick or temperature tests to evaluate small fiber function. Deep tendon reflexes, particularly at the ankle, are assessed to identify large fiber impairment. Quantitative Sensory Testing (QST), nerve conduction studies (NCS), and electromyography (EMG) are advanced procedures employed to verify the type and severity of neuropathy, particularly when the diagnosis is ambiguous or the symptoms are unusual.

Differential Diagnosis: Because of the variety of symptoms, DN needs to be distinguished from other types of peripheral neuropathy. Common differential diagnoses consist of chronic alcohol consumption, deficiencies in vitamin B12 or folate, thyroid issues (particularly hypothyroidism), uremic neuropathy due to chronic kidney disease, and neurological

disorders like chronic inflammatory demyelinating polyneuropathy (CIDP). These conditions might also occur alongside diabetes, complicating the diagnosis further. Assessing nutritional deficiencies, thyroid function, kidney parameters, and autoimmune markers assists in eliminating other potential or concurrent causes.

Suitable Treatment & Continued Care: The goal of pharmacological treatment for diabetic neuropathy is to manage symptoms and reduce progression. First-line treatments typically consist of antidepressants such as duloxetine, anticonvulsants like pregabalin and gabapentin, as well as tricyclic antidepressants including amitriptyline. For individuals experiencing both hypertension and nephropathy, angiotensin II receptor blockers (ARBs) such as losartan are especially beneficial. Losartan not only controls blood pressure but also lowers proteinuria and glomerular injury, providing renal protection that indirectly promotes nerve health by alleviating vascular strain.

Monitoring is essential for modifying treatment strategies based on symptom advancement, side effects of medications, and related complications. Routine assessments include tracking glycemic management (HbA1c), kidney function (serum creatinine, eGFR, urine albumin), and blood pressure. Collaborative care that includes endocrinologists, nephrologists, neurologists, and primary care providers improves the quality and continuity of treatment.

b) Treatment Options

Dosage: Losartan is typically started at 50 mg once a day for patients with diabetic nephropathy and related hypertension. Based on the response of blood pressure and kidney tolerance, the dosage may be adjusted to 100 mg per day. For patients with volume depletion or those taking diuretics, starting with a reduced dose might be advisable to prevent hypotension or acute kidney damage.

Supervision & Modification: After starting therapy with losartan, consistent monitoring is crucial to confirm its effectiveness and safety. Blood pressure needs to be monitored regularly to prevent it from dropping too low, especially in older adults. Renal function must be assessed through serum creatinine measurement and estimation of glomerular filtration rate (eGFR). Serum potassium levels must be checked to identify hyperkalemia, an established side effect of ARBs, particularly in individuals with worsening kidney function or those using potassium-sparing diuretics.

For patients experiencing inadequate response or adverse effects, treatment can be altered by changing the dose or exploring combination therapy with additional antihypertensive medications. If blood pressure stays uncontrolled, the inclusion of a calcium channel blocker or a low-dose thiazide diuretic could be contemplated.

Patient Instruction & Adherence: Efficient management of diabetic neuropathy relies not only on medication but also on patient involvement. Education must include the significance of managing blood glucose and blood pressure, the persistent nature of neuropathy, possible medication side effects, and changes in lifestyle. Patients must be advised to watch for indications of deteriorating neuropathy (e.g., new sores, alterations in sensation) and communicate them immediately.

Medication adherence can be enhanced by streamlining treatment plans, utilizing pill organizers, and establishing reminders. Supplying educational resources, engaging caregivers, and organizing consistent follow-ups also facilitate sustained adherence. Nutritional guidance, foot care education, and promotion of physical activities (such as walking and resistance training) enhance circulation and help avoid complications.

c) Relationship between Hypertension, Diabetes, Cardiac & Renal Issues Using Losartan

The combination of diabetes, hypertension, and kidney dysfunction forms a harmful cycle that greatly elevates the risk of neuropathy and cardiovascular incidents. Extended hyperglycemia leads to non-enzymatic protein glycation, heightened oxidative stress, and mitochondrial impairment, all of which result in endothelial damage and reduced nerve blood flow. At the same time, high blood pressure speeds up vascular remodeling, raising arterial stiffness and further hindering blood flow to the peripheral nerves and kidneys.

Losartan is vital in interrupting this harmful interaction. As an angiotensin II receptor antagonist, it specifically prevents the attachment of angiotensin II to the AT1 receptor, resulting in vasodilation, lowered aldosterone release, and diminished sodium and water retention. This measure aids in decreasing systemic blood pressure, alleviating glomerular hypertension, and reducing proteinuria, which indicates kidney injury.

In individuals with diabetic nephropathy, losartan has shown effectiveness in hindering the advancement of kidney disease. Research like the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) trial has demonstrated that losartan lowers the risk of doubling serum creatinine levels, developing end-stage renal disease, and experiencing proteinuria in individuals with type 2 diabetes and nephropathy.

From a neurological standpoint, better kidney function and blood pressure regulation could lead to improved nerve blood flow and oxygen supply. Certain preclinical research indicates that ARBs such as losartan might exhibit neuroprotective and anti-inflammatory properties, potentially by influencing oxidative stress and pro-inflammatory cytokine mechanisms. Although not currently a standard therapy for diabetic neuropathy, these characteristics imply a possible indirect advantage of losartan in reducing the progression of neuropathy.

Additionally, the cardiovascular advantages of losartan, including the reduction of left ventricular hypertrophy and arterial stiffness, enhance overall vascular health. These impacts

are especially significant for diabetic patients who face an increased risk of heart failure, stroke, and myocardial infarction.

In conclusion, losartan represents a multipurpose pharmacologic agent that addresses several key pathophysiological mechanisms in diabetes-related complications. Its application in individuals with diabetic neuropathy and concurrent hypertension or nephropathy not only enhances blood pressure and kidney results but might also provide protective advantages to the peripheral nervous system. Current research is further investigating these additional advantages, highlighting losartan's promise as a fundamental component in the holistic treatment of diabetes-associated vascular and neural issues.



Chapter 4: Losartan

a) Synthesis

Losartan is a man-made medication that falls under the category of angiotensin II receptor antagonists (ARBs), often known as sartans. The synthesis of losartan comprises various organic chemistry processes aimed at producing a molecule that can selectively attach to the angiotensin II type 1 (AT1) receptor.

Losartan's chemical structure features a biphenyl component with a tetrazole ring, crucial for AT1 receptor interaction, along with an imidazole ring that influences its pharmacokinetic characteristics. A typical synthetic pathway initiates with the creation of a biphenyl intermediate through Suzuki coupling. A tetrazole ring is subsequently formed via [3+2] cycloaddition of azides and nitriles, leading to the creation of an imidazole derivative. The last stages include substitution reactions to create the entire losartan molecule. Strategies for protecting groups are essential for ensuring selectivity, and the reaction conditions need to be meticulously managed because of the intermediates' sensitivity to acid and base.

Losartan is usually prepared as a potassium salt to enhance stability and absorption. It comes in different tablet strengths (25 mg, 50 mg, 100 mg) and is occasionally paired with hydrochlorothiazide (HCTZ) to improve blood pressure-lowering effects.

Indications:

- High blood pressure
- Neuropathy in type 2 diabetes affecting the kidneys
- Reducing stroke risk in hypertensive individuals with left ventricular hypertrophy.

Contraindications:

- Gestation (notably during the second and third trimesters)
- Bilateral renal artery narrowing
- Allergic reaction to losartan or any ingredient in the formulation

Precautions:

- Use carefully in individuals with kidney issues or liver dysfunction.
- Observe fluid levels in patients being treated with diuretics.
- Refrain from simultaneous use with other potassium-sparing medications unless closely supervised.

Storage: Losartan must be kept at a temperature of 20–25°C (68–77°F), shielded from light and humidity. The tablets must stay in their original packaging until they are needed.

Adverse Reactions: Frequent adverse reactions consist of:

- Vertigo
- Tiredness
- Low blood pressure (particularly following the initial dose)
- Hyperkalemia
- Increased serum creatinine
- Diarrhea and nasal congestion

Rare but serious adverse effects may include angioedema and acute kidney injury. Regular monitoring can mitigate these risks.

b) Mechanism of Action (MOA)

Target Location: Losartan specifically attaches to the angiotensin II type 1 (AT1) receptor, which is mainly located in vascular smooth muscle cells, adrenal glands, kidneys, and the

heart. By inhibiting these receptors, losartan obstructs the actions of angiotensin II, a strong vasoconstrictor.

Biological Impact: Angiotensin II generally stimulates vasoconstriction, sodium retention, aldosterone release, and sympathetic activation—factors that elevate blood pressure and lead to cardiovascular and kidney harm. Through the inhibition of AT1 receptor binding, losartan triggers vasodilation, lowers aldosterone secretion, and diminishes sodium and water retention. This results in a decrease in blood pressure, heart workload, and kidney glomerular pressure.

Pharmacodynamics: Losartan acts quickly, taking effect within 1 hour, with maximum impact occurring between 3 to 6 hours after administration. Its effects last for about 24 hours, permitting once-a-day administration. Losartan acts as a prodrug and undergoes metabolism in the liver to form its active metabolite, EXP3174, which exhibits higher potency and a more extended half-life compared to the original compound.

The medication demonstrates a dose-related antihypertensive effect and has proven effective in reducing proteinuria and decelerating the advancement of kidney disease in individuals with diabetes. In contrast to ACE inhibitors, losartan does not elevate bradykinin levels, which decreases the occurrence of dry cough and angioedema.

Selectivity: Losartan shows a strong selectivity for the AT1 receptor, exhibiting minimal affinity for the AT2 receptor. This selectivity aids in preventing unwanted effects linked to AT2 receptor activation, like tissue fibrosis. Furthermore, by not blocking ACE (as ACE inhibitors do), losartan maintains other vasodilatory mechanisms, like the one driven by bradykinin.

Overview of Pharmacokinetics: Absorption: Well absorbed when taken orally, with about 33% bioavailability Distribution: widely dispersed; more than 99 percent protein-bound Hepatic metabolism (CYP2C9, CYP3A4) Excretion: biliary and renal pathways; active metabolite half-life is approximately 6 to 9 hours. All things considered, losartan's two functions—lowering blood pressure and protecting end organs—make it a crucial part of treating complicated conditions like diabetic neuropathy, particularly in individuals who also have hypertension and renal issues. Research is still being conducted to assess its wider medicinal uses, including possible neuroprotective functions.

Statistics on Diabetic neuropathy on Losartan Use:

Parameter	**Value/Estimate**
Global prevalence of diabetes mellitus	~10% of adults worldwide (approx. 537 million people in 2021)
Prevalence of diabetic neuropathy among diabetics	30–50% of patients with diabetes develop some form of neuropathy during their lifetime
Percentage of patients with painful neuropathy	~16–26% of diabetics may develop painful neuropathy symptoms
Relative risk reduction in nephropathy with ARBs (like Losartan)	16–25% reduction in progression to overt nephropathy in type 2 diabetes (per clinical trials like RENAAL)
Common dosage range of Losartan for diabetic nephropathy	50–100 mg once daily
Estimated proportion of hypertensive diabetics using ARBs	~40–60% of hypertensive type 2 diabetic patients may receive an ARB as first-line or add-on therapy



Figure 1: Effect of losartan on SBP and DBP

This bar graph depicts the average systolic blood pressure (SBP) and diastolic blood pressure (DBP) figures of patients at baseline, as well as at 3 months and 6 months following the start of losartan treatment. The blue bars signify SBP while the orange bars indicate DBP. At baseline, the average SBP and DBP were 152.18 mmHg and 95.56 mmHg, respectively. Following 3 months of losartan treatment, these measurements decreased to 136.88 mmHg and 87.31 mmHg. At six months, additional declines were noted, with SBP falling to 126.78 mmHg and DBP to 82.68 mmHg. These results show the gradual antihypertensive impact of losartan as time passes, highlighting its effectiveness in reducing both systolic and diastolic blood pressures.

↓ SBP → Lessen harm to blood vessels and nerves

↓ DBP → Enhances microvascular blood flow

Ongoing impact for 6 months →Stable BP management hinders neuropathy advancement.

Treatment with losartan → Also improves kidney health and may decrease systemic inflammation.

Chapter 5: Advanced Technology

a) Combination Treatments, CRISPR & Gene Editing, Tailored Dosage, Nanotechnology-driven Drug Administration:

In recent years, major developments in biomedical technology have deepened our knowledge of diabetic neuropathy and refined methods for its treatment. Losartan, recognized for its roles in lowering blood pressure and protecting kidneys, is being further investigated in novel therapeutic frameworks that may enhance its application in more focused and personalized treatment approaches.

Combination Treatments: Combination treatments have emerged as a fundamental aspect of contemporary medicine, especially in intricate chronic illnesses such as diabetes and its associated complications. In diabetic neuropathy, treatment strategies frequently involve glucose-lowering medications, neuroprotective agents, and therapies focusing on vascular health. Losartan is often used in conjunction with other antihypertensive medications (e.g., calcium channel blockers, thiazide diuretics) to enhance blood pressure management. Additionally, it might be prescribed alongside antidiabetic medications like metformin or SGLT2 inhibitors to ensure thorough management of metabolic and vascular issues.

Clinical studies have investigated the use of losartan in combination with antioxidants (like alpha-lipoic acid), aldose reductase inhibitors, or nerve growth factor analogs to improve neuroprotective outcomes. The collaboration from these combinations offers potential in diminishing nerve inflammation and oxidative stress, key elements in the development of diabetic neuropathy.

CRISPR & Gene Therapy: The CRISPR-Cas9 gene-editing technology has surfaced as a groundbreaking method for rectifying genetic mutations on a molecular scale. In the realm of

diabetic neuropathy, CRISPR is being explored for its ability to address genes linked to glucose processing, inflammation, and nerve degeneration. Although still in initial preclinical stages, the potential to amend foundational genetic susceptibilities may change the course of disease development.

Gene therapy, utilizing viral or non-viral vectors to introduce therapeutic genes, is being developed to tackle neuropathic pain and enhance nerve regeneration. Although losartan is not utilized directly in gene therapy, its systemic advantages—specifically its anti-inflammatory and vascular-protective properties—could enhance these advanced treatments, particularly within multimodal therapeutic strategies.

Personalized Dosage: Pharmacogenomics, which examines the influence of genetics on an individual's drug response, is increasingly important in customizing medication plans. Genetic variations impacting losartan metabolism (particularly CYP2C9 and CYP3A4 enzymes) can affect the drug's efficacy and safety. Patients with decreased enzyme function might exhibit elevated levels of losartan in circulation, resulting in enhanced effectiveness or a greater chance of side effects.

Through the incorporation of pharmacogenetic testing, healthcare providers can tailor losartan dosages to enhance blood pressure management and kidney safety while reducing adverse effects. Personalized medicine platforms utilizing patient-specific genetic, metabolic, and lifestyle information can more accurately stratify risk, predict therapeutic response, and suggest dosage modifications compared to traditional protocols.

Nanotechnology-Enhanced Drug Delivery: Nanotechnology provides innovative drug delivery systems that boost bioavailability, enhance drug targeting, and minimize systemic toxicity. Nanoparticle-based delivery systems like liposomes, solid lipid nanoparticles, and

polymeric nanoparticles are being explored for losartan to enhance its pharmacokinetic characteristics.

These nanocarriers can enclose losartan, shield it from enzymatic breakdown, and transport it straight to target tissues—like the kidneys or peripheral nerves—where it is required the most. For instance, directed delivery to the kidney glomeruli could improve nephroprotection while reducing systemic exposure. Certain research has investigated ligand-anchored nanoparticles that attach to particular receptors found in inflamed or ischemic tissues, guaranteeing accurate drug delivery.

Moreover, the creation of hybrid nanocarriers that can simultaneously deliver losartan alongside other medications (such as antioxidants or anti-inflammatory drugs) marks a considerable advancement in the treatment of complex diseases like diabetic neuropathy. These advancements not only enhance therapeutic results but could also decrease dosing frequency, improve adherence, and lessen side effects.

Intelligent Drug Delivery Systems: Innovative technologies like stimuli-responsive delivery mechanisms (reacting to pH, temperature, or glucose concentrations) are under investigation for the regulated and targeted release of medications such as losartan. These systems might be able to modify the drug delivery depending on a patient's physiological state, enhancing the adaptability and effectiveness of the treatment.

Integration of Wearable and Implantable Technology: Wearable biosensors along with implantable drug delivery systems are capable of monitoring physiological parameters instantaneously (such as glucose levels, blood pressure) and modifying drug delivery as needed. While still primarily in the experimental stage, incorporating losartan administration into these systems could enable adaptive dosing approaches in reaction to variations in

patient condition, especially for those with unstable blood pressure or worsening kidney function.

Intelligent Systems and Forecasting Models: AI-based platforms are currently utilized to foresee disease advancement, treatment outcomes, and medication interactions. Machine learning models can combine information from electronic health records, genomics, and wearable devices to help clinicians establish ideal treatment plans that might involve losartan. Predictive analytics can determine which patients would gain the most from ARB therapy and customize dosing according to personalized risk profiles.

In summary, Chapter 5 emphasizes the ways in which advanced technological advancements are revolutionizing the treatment of diabetic neuropathy and improving the efficacy of conventional medications such as losartan. Utilizing combination therapies, genetic technologies, tailored dosing, and nanotech, the range and accuracy of losartan's usage are greatly enhanced, aligning treatments with the objectives of contemporary precision medicine.

Chapter 6: Limitations & Future Indications

a) Limitations

Losartan, while widely used in clinical practice, has several limitations that must be recognized, particularly in cases of diabetic neuropathy combined with comorbidities such as hypertension and nephropathy. These constraints relate to expense, accessibility, age-related safety, genetic diversity, and the possibility of tolerance with prolonged usage.

Cost & Availability: While losartan is offered as a generic drug and is typically affordable in various countries, differences in healthcare systems and access to pharmaceuticals can pose considerable obstacles. In low-income or rural areas, generic medications may be limited in supply or too expensive. Additionally, combination medications (such as losartan paired with hydrochlorothiazide) might not always be accessible, limiting treatment alternatives and care continuity.

Age Limitations: Losartan is generally not advised for use in children, particularly those under six years old, unless it is given under specific pediatric hypertension guidelines. Safety information in very young patients is scarce, and age-related variations in drug metabolism and organ sensitivity require careful consideration. In older adults, greater sensitivity to losartan can result in low blood pressure or kidney dysfunction, particularly when taken alongside other blood pressure medications or diuretics.

Genetic Influences: Variability in pharmacogenetics significantly impacts the metabolism and effectiveness of losartan. The cytochrome P450 enzymes, notably CYP2C9 and CYP3A4, play a key role in transforming losartan into its active form, EXP3174. Variations in these enzymes can greatly affect the response to treatment. Individuals with diminished enzyme activity might undergo inadequate transformation of losartan, leading to less effective blood

pressure management. Moreover, alterations in the angiotensin receptor gene (AGTR1) can affect receptor sensitivity and lead to discrepancies in response.

Tolerance Development: Although genuine pharmacologic tolerance to ARBs, such as losartan, is uncommon, certain patients might notice a reduced therapeutic effect as time goes on, especially with the progression of renal or cardiovascular diseases. In these situations, increasing the dosage or using additional medications might be necessary, potentially raising the risk of side effects or interactions with other drugs.

Negative Effects and Precautions: Continuous use of losartan necessitates consistent evaluation because of possible side effects including hyperkalemia, increased serum creatinine, and, infrequently, angioedema. Individuals with bilateral renal artery stenosis or those who are expectant must refrain from using losartan because of the potential for fetal harm and kidney issues. These constraints require meticulous patient selection and continual clinical monitoring.

b) Future Predictions

The realm of drug repurposing and innovation is continuously changing, and losartan has attracted interest beyond its conventional uses. Future indications and research avenues encompass innovative applications in neuroprotection, anti-inflammatory effects, fibrosis mitigation, and therapies aimed at modifying diseases across several systemic disorders.

Current clinical trials are assessing losartan's efficacy in alleviating the impact of diabetic complications other than nephropathy. For instance, research is investigating its function in inhibiting the advancement of diabetic neuropathy via mechanisms that include vascular and neural safeguarding. Studies indicate that ARBs might lower oxidative stress and enhance endothelial function, vital for maintaining nerve integrity.

Studies like NCT04226008 and others investigate the impact of losartan in treating inflammatory neuropathies or reducing microvascular complications in individuals with metabolic syndrome. Preclinical research indicates that losartan might influence pathways related to nerve inflammation and demyelination, suggesting it could serve as a potential supplementary treatment for neurodegenerative disorders.

Drug Repurposing: The anti-inflammatory and antifibrotic effects of losartan have generated interest in its use for conditions outside of cardiovascular issues. In light of the COVID-19 pandemic, losartan was studied for its potential effectiveness in reducing lung damage due to its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor. Additional areas of investigation encompass hepatic fibrosis, Alzheimer's disease, and specific cancer types where the renin-angiotensin system (RAS) plays a role in pathogenesis.

Regulatory & Approval Status: Losartan is presently authorized by the U.S. FDA and EMA for managing hypertension, diabetic nephropathy, and for lowering the risk in patients with left ventricular hypertrophy. Nevertheless, off-label usage frequently occurs in clinical settings, especially among patients with various comorbid conditions. Future signals will rely on the results of current trials and later regulatory assessments. Broadened indications may result in revised prescribing recommendations and greater clinical use.

Competitor Medications and New Options: Although losartan is effective and well-tolerated, multiple other ARBs (including irbesartan, candesartan, and telmisartan) are undergoing research for comparable or improved therapeutic effects. Some possess greater receptor-binding affinity or extended half-lives, possibly providing better efficacy or dosing ease. Moreover, recent drug classes, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists, have demonstrated considerable cardiovascular and

renal advantages in diabetic individuals and could provide complementary or alternative treatment options.

Research is ongoing into combination therapy with losartan and newer agents to identify any additive or synergistic advantages, especially in alleviating the impact of diabetic complications.

Innovative Delivery Systems: As mentioned in Chapter 5, cutting-edge delivery methods like nanoparticles and prolonged-release implants are being developed to improve the effectiveness and patient compliance related to losartan. These sophisticated systems could be integral to the upcoming era of chronic disease management solutions.

In Conclusion, Chapter 6 emphasises the significance of acknowledging losartan's present drawbacks while showcasing its potential for the future. Access issues, side effect profiles, and genetic diversity call for a customised and closely watched strategy. At the same time, developments in molecular medicine and pharmacology present encouraging opportunities to expand the use of losartan into other areas, such as inflammation and neurodegeneration. Losartan may transform from a common antihypertensive into a flexible therapeutic tool that addresses several facets of diabetes and systemic disease with more study and development.

Chapter 7: Conclusion

Managing diabetic neuropathy is a complicated clinical issue because of its multiple causes and its common links to other conditions like hypertension, nephropathy, and cardiovascular disease. Losartan, a commonly used angiotensin II receptor blocker (ARB), stands out as a potential treatment option because of its distinctive ability to engage with these various disease pathways. By lowering blood pressure, decreasing proteinuria, enhancing endothelial function, and possibly providing anti-inflammatory and neuroprotective benefits, losartan has transformed from a basic antihypertensive medication into a versatile asset in the management of chronic diseases.

The thorough analysis throughout the previous chapters shows that losartan's benefits extend beyond just controlling blood pressure. It offers kidney protection, slows down the advancement of diabetic nephropathy, and might aid in improved nerve blood flow and metabolic stabilization in individuals with diabetic neuropathy. Its pharmacological characteristics—including AT1 receptor selectivity, active metabolite profile, and an acceptable safety margin—highlight its appropriateness for prolonged use in individuals with complications related to diabetes.

Furthermore, technological progress is transforming how conventional medications such as losartan are used. Combining therapies with other antidiabetic, antioxidant, or neuroprotective agents; potential uses for CRISPR and gene editing; personalized dosing guided by pharmacogenomic profiles; and nanotechnology-enabled delivery systems all indicate a shift toward a more targeted and individualized treatment strategy. These advancements not only improve the effectiveness of the drug but also minimize overall exposure and adverse effects.

Even with these improvements, challenges persist. Challenges like differing drug responses from genetic variations, the likelihood of side effects in certain groups, financial access hurdles, and restricted indications for children need to be tackled. Yet, continuous studies and drug repurposing efforts suggest that losartan's application could extend even more—potentially into neurodegenerative disorders, inflammatory diseases, and as a component of tailored medicine programs.

As we progress into a time of tailored and comprehensive care, losartan’s wide range of uses and developing characteristics present healthcare providers a beneficial choice for addressing diabetic neuropathy and its related issues. It emphasizes the significance of considering medications not as standalone elements, but rather within a holistic, interdisciplinary care framework that encompasses lifestyle management, early diagnosis, ongoing monitoring, and patient education.

References

1. Brenner, B. M., et al. (2001). “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.” The New England Journal of Medicine, 345(12), 861–869.

2. American Diabetes Association. (2024). “Standards of Medical Care in Diabetes.” Diabetes Care, 47(Suppl. 1): S1–S296.

3. Molitch, M. E., et al. (2004). “Nephropathy in diabetes.” Diabetes Care, 27(Suppl 1), S79–S83.

4. Burnier, M. (2001). “Pharmacokinetics and pharmacodynamics of angiotensin II receptor blockers.” Clinical Pharmacokinetics, 40(9), 601–613.

5. Baral, P., et al. (2022). “CRISPR-Cas9 and its Applications in Precision Medicine.” Journal of Molecular Medicine, 100(3), 275–287.

6. Zhang, Y., et al. (2021). “Nanoparticle-based drug delivery systems for diabetic complications.” International Journal of Nanomedicine, 16, 123–145.

7. Suarez-Kurtz, G. (2010). “Pharmacogenomics in the treatment of hypertension.” Pharmacogenomics Journal, 10(6), 385–395.

8. Santos, R. A. S., et al. (2018). “The renin-angiotensin system: going beyond the classical paradigms.” American Journal of Physiology, 314(6), R889–R901.

9. ClinicalTrials.gov. (2024). “Ongoing trials exploring losartan in neuroinflammation and systemic complications.” Retrieved from: https://clinicaltrials.gov

10. Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., & Osicka, T. M. (2002). Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes, 51(11), 3274–3282. https://doi.org/10.2337/diabetes.51.11.3274

11. Selby, N. M., & Taal, M. W. (2020). An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obesity and Metabolism. Advance online publication. https://doi.org/10.1111/dom.14007

12. Miao, Y., Ottenbros, S. A., Laverman, G. D., Brenner, B. M., Cooper, M. E., Parving, H.-H., Grobbee, D. E., Shahinfar, S., de Zeeuw, D., & Lambers Heerspink, H. J. (2011). Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. Hypertension, 58(1), 2–7. https://doi.org/10.1161/HYPERTENSIONAHA.111.171488

13. Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P., for the VA NEPHRON-D Investigators. (2013). Combined angiotensin inhibition for the treatment of diabetic nephropathy. The New England Journal of Medicine, 369(20), 1892–1903. https://doi.org/10.1056/NEJMoa1303154

14. Herman, W. H., Shahinfar, S., Carides, G. W., Dasbach, E. J., Gerth, W. C., Alexander, C. M., Cook, J. R., Keane, W. F., & Brenner, B. M., for the RENAAL Investigators. (2003). Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Diabetes Care, 26(3), 683–687. https://doi.org/10.2337/diacare.26.3.683

15. Kwakernaak, A. J., Krikken, J. A., Binnenmars, S. H., Visser, F. W., Hemmelder, M., Woittiez, A.-J., Groen, H., Laverman, G. D., & Navis, G., on behalf of the Holland Nephrology Study (HONEST) Group. (2014). Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised

clinical trial. The Lancet Diabetes & Endocrinology, Published online March 5, 2014. https://doi.org/10.1016/S2213-8587(14)70030-0

16. Strippoli, G. F. M., Craig, M., Deeks, J. J., Schena, F. P., & Craig, J. C. (2004). Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ, 329(7470), 828. https://doi.org/10.1136/bmj.38237.585000.7C

17. Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005). Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care, 28(8), 2106–2112. https://doi.org/10.2337/diacare.28.8.2106

18. Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2010). The rAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology, 6(6), 319–330. https://doi.org/10.1038/nrneph.2010.58

19. Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Parikh, C. R., Raz, I., Vanhille, P., Wiegmann, T. B., Wolfe, B. M., Locatelli, F., Goldhaber, S. Z., & Lewis, E. J. (2003). Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine, 138(7), 542–549. https://doi.org/10.7326/0003-4819-138-7-200304010-00005

20. Van Buren, P. N., & Toto, R. (2010). Hypertension in diabetic nephropathy: Epidemiology, mechanisms, and management. American Journal of Kidney Diseases, 55(3), S27–S37. https://doi.org/10.1053/j.ajkd.2009.12.017

21. Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L., & Parving, H.-H. (2004). Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic

nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia, 47(11), 1936–1939. https://doi.org/10.1007/s00125-004-1542-0

22. Campistol, J. M., Iñigo, P., Jimenez, W., Lario, S., Clesca, P. H., Oppenheimer, F., & Rivera, F. (1999). Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney International, 56(2), 714–719. https://doi.org/10.1046/j.1523-1755.1999.00611.x

23. Lim, A. K. H. (2014). Diabetic nephropathy—Complications and treatment. International Journal of Nephrology and Renovascular Disease, 7, 361–381. https://doi.org/10.2147/IJNRD.S40172

24. Leehey, D. J., Singh, A. K., Alavi, N., & Singh, R. (2000). Role of angiotensin II in diabetic nephropathy. Kidney International, 58(Suppl. 77), S93–S98.

25. De Zeeuw, D., Ramjit, D., Zhang, Z., Ribeiro, A. B., Kurokawa, K., Lash, J. P., Chan, J., Remuzzi, G., Brenner, B. M., & Shahinfar, S. (2006). Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International, 69(9), 1675–1682. https://doi.org/10.1038/sj.ki.5000326

26. Herman, W. H., Shahinfar, S., Carides, G. W., Dasbach, E. J., Gerth, W. C., Alexander, C. M., Cook, J. R., Keane, W. F., & Brenner, B. M. (2003). Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Diabetes Care, 26(3), 683–687. https://doi.org/10.2337/diacare.26.3.683

27. Lacourcière, Y., Bélanger, A., Godin, C., Hallé, J.-P., Ross, S., Wright, N., & Marion, J. (2000). Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney International, 58(Suppl. 75), S93–S98.

28. Kavgacı, H., Şahin, A., Ersöz, H. Ö., Erem, C., & Özdemir, F. (2002). The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Research and Clinical Practice, 58(1), 19–25. https://doi.org/10.1016/S0168-8227(02)00102-X

29. Gong, X., Liu, J., Guo, H., & Zhang, W. (2025). Clinical efficacy of losartan potassium combined with alprostadil in early diabetic nephropathy and its effect on renal function. Pakistan Journal of Medical Sciences, 41(6), 1567–1571. https://doi.org/10.12669/pjms.41.6.10796

30. Schernthaner, G. (2008). Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy? Nature Reviews Nephrology, 4, 656–657. https://doi.org/10.1038/ncpneph0962

31. Smith et al. (2022). The role of angiotensin receptor blockers in the personalized management of diabetic neuropathy. Journal of Personalized Medicine, 12(8), 1253. https://doi.org/10.3390/jpm12081253

32. Ayli, M., Tüfekçioğlu, O., Ensari, C., Erbaşı, S., Ayli, D., & Sabah, İ. (2001). Effects of losartan on blood pressure and microalbuminuria in hypertensive type 2 diabetic patients. Turkish Journal of Nephrology, 10(1), 53–56.

33. Rossing, P., et al. (2003). Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype. Diabetes Care, 26(5), 1501–1506.

34. Ersoz, H. Ö., Gogas, D., Budak, Y., & Akalin, S. (1997). The effect of specific angiotensin receptor antagonist losartan on diabetic nephropathy in a diabetic rat model. Turkish Journal of Nephrology, 6(2), 106–111.

35. Kavgacı, H., Şahin, A., Ersöz, H. Ö., Erem, C., & Özdemir, F. (2002). The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Research and Clinical Practice, 58, 19–25.

36. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., … Shahinfar, S. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine, 345(12), 861–869. https://doi.org/10.1056/NEJMoa011161

37. Ohno, Y., Nishimura, A., Iwai, H., Hirota, N., Yamauchi, T., Fujimoto, M., & Arai, H. (2007). Anti‐albuminuric effect of losartan versus amlodipine in hypertensive Japanese patients with type 2 diabetes mellitus: A prospective, open‐label, randomized comparison. Current Therapeutic Research–Clinical and Experimental, 68(2), 94–106. https://doi.org/10.1016/j.curtheres.2006.06.001

38. Aylı, M., Tüfekçioğlu, O., Ensari, C., Erbaşı, S., Aylı, D., & Sabah, İ. (2001). Effects of losartan on blood pressure and microalbuminuria in hypertensive type 2 diabetic patients. Turkish Journal of Nephrology, 10(1), 53–56. https://turkjnephrol.org/en/effects-of-losartan-on-blood-pressure-and-microalbuminurea-in-hypertensive-type-2-diabetic-patients-136520

39. The RENAAL Study Group. (2003). Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus: A randomized clinical trial. Annals of Internal Medicine, 139(2), 124. https://pubmed.ncbi.nlm.nih.gov/12859158

40. Khan, A. H., & Abbas, M. (2009). Reduction of microalbuminuria by losartan in normotensive type 2 diabetic patients: A randomized trial. Pakistan Journal of Medical Sciences, 25(1), 24–28. https://pubmed.ncbi.nlm.nih.gov/19414946


turnitin.com/assignmer
Premium buzz | User Info | Messages | Student | English | Community | Help | Logout
turnitin
Class Portfolio
NOW VIEWING: HOME > NURSING > 27
About this page
This is your assignment dashboard. You can upload submissions for your assignment from here. When a submission has been processed you will be able to download a digital receipt, view any grades and similarity reports that have been made available by your instructor.
27
Paper Title
Uploaded
Grade
Similarity
thesis 3
07/19/2025 8:09 PM
--
17%
Copyright © 1998-2025 Turnitin, LLC. All Rights Reserved. (Privacy Policy)
Helpdesk
Research Resources